» Articles » PMID: 34899827

Exploration of Potential MiRNA Biomarkers and Prediction for Ovarian Cancer Using Artificial Intelligence

Overview
Journal Front Genet
Date 2021 Dec 13
PMID 34899827
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is the second most dangerous gynecologic cancer with a high mortality rate. The classification of gene expression data from high-dimensional and small-sample gene expression data is a challenging task. The discovery of miRNAs, a small non-coding RNA with 18-25 nucleotides in length that regulates gene expression, has revealed the existence of a new array for regulation of genes and has been reported as playing a serious role in cancer. By using LASSO and Elastic Net as embedded algorithms of feature selection techniques, the present study identified 10 miRNAs that were regulated in ovarian serum cancer samples compared to non-cancer samples in public available dataset GSE106817: hsa-miR-5100, hsa-miR-6800-5p, hsa-miR-1233-5p, hsa-miR-4532, hsa-miR-4783-3p, hsa-miR-4787-3p, hsa-miR-1228-5p, hsa-miR-1290, hsa-miR-3184-5p, and hsa-miR-320b. Further, we implemented state-of-the-art machine learning classifiers, such as logistic regression, random forest, artificial neural network, XGBoost, and decision trees to build clinical prediction models. Next, the diagnostic performance of these models with identified miRNAs was evaluated in the internal (GSE106817) and external validation dataset (GSE113486) by ROC analysis. The results showed that first four prediction models consistently yielded an AUC of 100%. Our findings provide significant evidence that the serum miRNA profile represents a promising diagnostic biomarker for ovarian cancer.

Citing Articles

Differential circulating miRNA profiles identified miR-423-5p, miR-93-5p, and miR-4532 as potential biomarkers for cholangiocarcinoma diagnosis.

Supradit K, Prasopdee S, Phanaksri T, Tangphatsornruang S, Pholhelm M, Yusuk S PeerJ. 2024; 12:e18367.

PMID: 39677943 PMC: 11639864. DOI: 10.7717/peerj.18367.


miR-5100 Overexpression Inhibits Prostate Cancer Progression by Inducing Cell Cycle Arrest and Targeting E2F7.

Zhang A, Deng W, Shang H, Wu J, Zhang Y, Zhuang Q Curr Issues Mol Biol. 2024; 46(11):13151-13164.

PMID: 39590378 PMC: 11592579. DOI: 10.3390/cimb46110784.


Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.


Identifying factors related to mortality of hospitalized COVID-19 patients using machine learning methods.

Hamidi F, Hamishehkar H, Azari Markid P, Sarbakhsh P Heliyon. 2024; 10(15):e35561.

PMID: 39170355 PMC: 11337730. DOI: 10.1016/j.heliyon.2024.e35561.


High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.


References
1.
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R . Epithelial ovarian cancer: An overview. World J Transl Med. 2014; 3(1):1-8. PMC: 4267287. DOI: 10.5528/wjtm.v3.i1.1. View

2.
Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

3.
Nam E, Yoon H, Kim S, Kim H, Kim Y, Kim J . MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008; 14(9):2690-5. DOI: 10.1158/1078-0432.CCR-07-1731. View

4.
Hassanipour S, Ghaem H, Arab-Zozani M, Seif M, Fararouei M, Abdzadeh E . Comparison of artificial neural network and logistic regression models for prediction of outcomes in trauma patients: A systematic review and meta-analysis. Injury. 2019; 50(2):244-250. DOI: 10.1016/j.injury.2019.01.007. View

5.
Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View